Zheng Quan Ri Bao·2025-09-23 16:33Group 1 - The "Shareholders Are Coming" series of events organized by the Beijing Listed Companies Association aims to protect investor rights and facilitate communication between investors and listed companies [1][4] - The events featured three listed companies in the biopharmaceutical sector: Sanyuan Gene, China Pharmaceutical, and Ganli Pharmaceutical, showcasing their strengths in technological innovation and industry upgrades [2][3] Group 2 - Sanyuan Gene is a leading enterprise in the field of gene engineering drugs, with its main product being human interferon α1b, which is China's first gene engineering drug with independent intellectual property rights [2][5] - China Pharmaceutical has become an important platform for the China General Technology Group, focusing on an integrated development model in the pharmaceutical and medical device sectors, covering the entire industry chain from cultivation to international trade [3][5] - Ganli Pharmaceutical has achieved significant market competitiveness, ranking first in the procurement agreement volume for insulin analogs in 2024, and is actively expanding into the medical device sector [3][5] Group 3 - The series of events provided a platform for investors to engage with company management on key topics such as the development prospects of the biopharmaceutical industry and corporate strategies [4][5] - Company executives shared insights on their operational data, business models, and the challenges faced, emphasizing the importance of transparent communication with investors [5]